帕罗西汀与阿米替林治疗躯体形式障碍对照研究.docVIP

帕罗西汀与阿米替林治疗躯体形式障碍对照研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：帕罗西汀与阿米替林治疗躯体形式障碍对照研究 1 1 对象与方法 2 2 结果 3 3 讨论 4 文2：文拉法辛与阿米替林治疗抑郁症对照研究 5 1 对象与方法 6 2 结果 7 3 讨论 8 参考文摘引言： 8 原创性声明（模板） 10 文章致谢（模板） 10 正文 帕罗西汀与阿米替林治疗躯体形式障碍对照研究 文1：帕罗西汀与阿米替林治疗躯体形式障碍对照研究 A control study of paroxetive and amitriptyline in the treatment of somatoform disorde 【Abstract】 Objective To compare the curative effects and safety of paroxetive and amitriptyline in the treatment of somatoform disorde. Methods 66 patients with somatoform disorder were randomly divided into research(paroxetive, n=36）and control(amitriptyline, n=30）groups for 6 weeks. Before treatment and at the ends of the 2nd, 4th and 6th week of treatment, the clinical effects were assessed with the Hamilton Depression Scale(HAMD) and the Hamilton Anxiety Scale(HAMA),and advee effects with the Treatment Emergent Symptom Scale(TESS), respectively. Results At the ends of the 2nd, 4th and 6th week, compared with pretreatment the total scores of the HAMD or the HAMA and each factor’s score decreased significantly or very for both groups(P or ), and in corresponding period there was no significant difference between the 2 groups(all P). Incidence of the advee effects was lower and milder in the research than in the control group, differences were significant or very(P or ). Conclusion Paroxetive has therapeutic equivalence to amitriptyline, higher safety and better compliance in somatoform disorde. 【Keywords】 Paroxetive; amitriptyline; somatoform disorde; curative effect; safety 躯体形式障碍是一类以各种躯体症状为临床表现的精神障碍，患者常反复陈述躯体不适，但躯体和实验室检查未有相应的器质性疾患基础，既使存在某些躯体异常也不能解释患者症状的性质、严重程度等。患者常伴有焦虑抑郁症状，反复到综合 医院 就诊［1］。既往多使用阿米替林治疗，因其所致的口干，便秘，嗜睡等不良反应影响了患者治疗的依从性。有 文献 报道［2］，SSRIs对躯体形式障碍患者疗效显著，本研究采用帕罗西汀治疗躯体形式障碍并进行了对照研究，以探讨其疗效及安全性，现报告如下。 1 对象与方法 对象 选取2004年8月～2006年5月在我院门诊或住院治疗的66例躯体形式障碍患者为研究对象。入组标准：（1）符合《 中国 精神障碍分类与诊断标准》第3版（CCMD3）躯体形式障碍诊断标准。（2）排除躯体疾病，抑郁症，药物滥用及妊娠期妇女。将入组病例随机分为两组，研究组36例，男7例，女29例，年龄28 a～66 a，平均（±） a；病程9 mo～23 a，平均（±） a。对照组30例，男5例